The One Blood Sugar Sentence FDA Wrote Out for You

which blood sugar sentence did fda publish as permitted?

FDA published exactly this sentence as lawful: 'use as part of your diet to help maintain a healthy blood sugar level.' It comes from the agency's response to comment 75 in the January 2000 structure/function final rule — the rulemaking that still governs every dietary-supplement claim in this vertical today. Read it slowly: it names a bodily level, not a diagnosis, and it commits to maintenance rather than correction.

We checked this sentence against all ten disease-claim triggers at 21 CFR 101.93(g)(2), and it clears every one. It names no drug, no disease and no therapy. Run it on your label and the product still needs the standard disclaimer, printed in bold no smaller than one-sixteenth inch, sitting directly next to the claim with nothing in between. For the fuller buyer and market picture behind this niche, see our overview of the blood sugar supplement niche.

That sentence is the ceiling. Nothing else about glucose needs to be said.

which near-identical sentence did fda call a disease claim?

FDA published the forbidden twin in the same paragraph: 'Use as part of your diet when taking insulin to help maintain a healthy blood sugar level.' Compare the two sentences word for word and only one clause differs — 'when taking insulin.' Everything else, including the maintenance verb and the blood-sugar-level object, stays identical.

FDA's own reasoning for the rejection is blunt: 'Persons who take insulin have a disease, namely, diabetes.' The forbidden sentence doesn't say 'diabetes' anywhere, and it still failed, because naming the drug someone with diabetes takes does the same regulatory work as naming the disease itself.

This is the cleanest before/after FDA has ever published for this niche. Most agency reasoning stays abstract; here you get the exact sentence, the exact rejection and the exact fix, all inside one comment response from a single rulemaking.

why does mentioning insulin destroy an otherwise lawful claim?

Mentioning insulin destroys the claim because it links your product to a drug that treats a named disease, and FDA treats that link as a treatment claim on its own. The mechanism sits in two places at once: 21 CFR 101.93(g)(2)(vi), which bars claiming a product 'is a substitute for a product that is a therapy for a disease,' and (g)(2)(vii), which bars claiming it augments a particular therapy or drug action. Pairing your supplement with insulin, for the same purpose insulin serves, trips both at once.

FDA spelled out the fix in the same breath it explained the failure: 'Deleting the reference to the drug, insulin, would remove the implication.' Not softening it. Not qualifying it. Deleting it.

Here's the part advertisers usually get wrong first: they assume the fix is to swap 'insulin' for a gentler word, or to wrap the same comparison in a hedge — 'works alongside your diabetes medication,' 'a natural complement to insulin therapy,' 'supports what your prescription is already doing.' We changed our mind about this once ourselves, reading these letters early on and assuming softer verbs would clear the bar. They don't. The (g)(2)(vi) and (vii) triggers key on the relationship being claimed — substitution or augmentation of a disease therapy — not on the specific noun used to name the drug. Any construction that puts your product in a stated relationship to a prescription diabetes therapy inherits the same problem insulin created, however the sentence is dressed up.

does the same logic apply to metformin, a1c and prediabetes?

Yes for metformin, and yes for A1c readings tied to a diagnosis — the statutory triggers don't care which drug or which lab value you name, only that you've linked your product to a disease therapy or its characteristic markers. FDA's September 7, 2021 letter to Lysulin, Inc. shows exactly how a lab-value claim fails even without ever mentioning insulin or metformin by name.

FDA quoted the company's own copy as drug evidence: 'The combination and high level of these active ingredients have been shown to help maintain healthy A1c blood sugar levels in diabetics and prediabetics.' Strip the closing clause — 'in diabetics and prediabetics' — and what's left reads close to FDA's own permitted sentence. The population reference is what convicts it, not the ingredient claim.

Prediabetes sits in a genuinely uncertain spot. We could not find any FDA document that treats prediabetes differently from diagnosed diabetes for claim purposes — the Lysulin letter names both in the same breath, as one disqualifying population. Until FDA publishes something narrower, treat any copy naming a prediabetic audience as carrying the same risk as naming diabetics outright, and check the current warning-letter index yourself before relying on any gap you think you've found.

what does 'already within the normal range' add legally?

It adds the word that separates maintenance from correction, and FDA's own blood-sugar sentence skips it — unlike the cholesterol version. For cholesterol, FDA required the qualifier 'that are already within the normal range' before it would accept a maintenance claim, a distinction we laid out fully in the cholesterol sentence FDA wrote out. The blood-sugar sentence FDA blessed doesn't carry that exact phrase, but the same underlying test governs it.

FDA's general principle, stated elsewhere in the same rulemaking, is that a claim to maintain normal function isn't ordinarily a disease claim when nothing in the context suggests treatment. That's the load-bearing idea behind the permitted blood-sugar sentence even without the explicit normal-range wording attached to it.

Here's the part most advertisers miss entirely: FDA has separately held that 'maintain' language collapses into an implied treatment claim once the ad's own targeting establishes that the audience's baseline is already abnormal — the reasoning it used to kill 'maintain normal urine flow in men over 50,' since diminished flow is the norm in that population. Nothing published applies that specific reasoning to blood sugar, but the logic transfers cleanly: an ad aimed squarely at people who already know their glucose readings run high is describing 'maintenance' to an audience whose baseline the ad itself frames as unhealthy, which sits closer to a treatment claim than a maintenance one.

how does the permitted sentence perform against real market copy?

It performs poorly, and FDA has the receipts. The Lysulin letter wasn't an isolated case — it was one of ten warning letters FDA's food-and-supplement division issued on the same day, September 7, 2021, all targeting diabetes claims in a single coordinated sweep. Lay FDA's permitted sentence next to what the agency actually quoted from the Lysulin warning letter, and the gap is stark.

The hashtags matter as much as the headline claim did. FDA cited Instagram posts carrying tags like '#type2diabetic' and '#insulinresistance' as evidence of intended use, alongside a customer testimonial reporting A1c dropping from 10.5% to 9.5%. The letter also notes that the FTC reviewed the same websites the same month — both agencies were reading the identical pages, at the identical time.

what has to change on a lander built around glucose control?

Five things, and none of them are wording tweaks to the headline claim alone. FDA and FTC both read the whole funnel — landing page, ingredient tab, blog and social account — as a single body of evidence, so a fix has to run the same width.

Even a claim that survives FDA's disease-claim test still has to survive FTC's substantiation floor, and that's a separate and independent requirement. FTC's Health Products Compliance Guidance requires evidence at the level of the whole formula, not the individual ingredient — a distinction the agency won on summary judgment in FTC v. Wellness Support Network because ingredients can interact in ways a single-nutrient study won't show. A blend of nine studied ingredients, each with its own citation, is not the same thing as one clinical trial run on the product you actually sell.

FDA drew this same kind of precise line in other verticals too — it blessed an exact permitted phrase for bloating claims using the same maintenance-not-correction test.

The same discipline applies to stress and calm claims: find FDA's blessed sentence, then stop there.

• Cut any comparison to insulin, metformin, or 'your prescription' — substitution and augmentation claims are barred under 101.93(g)(2)(vi)-(vii) regardless of how the comparison is phrased
• Remove audience language naming diagnosed populations — 'diabetics,' 'prediabetics,' 'insulin resistance' — from landing-page copy, hashtags and testimonials alike
• Replace 'reduce,' 'lower' and 'reverse' with 'maintain... already within the normal range' wherever glucose or A1c is mentioned
• Audit the ingredient-education pages and organic social accounts on the same domain, not just the paid landing page
• Print the 21 CFR 101.93(c) disclaimer in bold, no smaller than one-sixteenth inch, immediately adjacent to the claim

Quick decision checklist

Use this page as a decision aid, not a generic blog post. The practical question is whether the reader needs faster evidence about what is already working in VSL-driven direct response, especially across nutra, supplements, GLP-1, weight loss, blood sugar, and adjacent high-intent health markets.

Daily Intel Service is most relevant when the next decision depends on active market examples: which hook to test, which claim style is risky, which funnel structure is common, which language market is moving, and whether a competitor's creative is likely early, scaling, or already saturated.

• Start with the TL;DR if you need the direct answer.
• Use the table to compare trade-offs quickly.
• Use the FAQ for answer-engine-ready summaries.
• Use the CTA when the decision requires live VSL and ad examples instead of theory.

Daily Intel's coverage advantage

Daily Intel Service is positioned around category-leading variety and actionability: one of the broadest direct-response catalogs of VSLs and ad creatives across blackhat, greyhat, and whitehat advertising patterns, with enough context to understand what the advertiser is doing beyond the visible creative. The practical difference is that members are not just seeing a screenshot; they are seeing the VSL, the ad, the funnel path, the transcript, the UTM context, and the research notes that turn the asset into a decision.

This matters because direct-response affiliates do not operate in one clean category. A weight-loss campaign may use a whitehat compliance ad, a greyhat pre-lander, a more aggressive VSL, and a checkout path designed around upsells and recovery. A useful intelligence platform needs to capture that spectrum instead of pretending every winning campaign looks like a public brand ad.

Blackhat, whitehat, and multilingual signal coverage

Daily Intel tracks patterns across both blackhat-style and whitehat-style campaigns so operators can understand the market without blindly copying risk. Whitehat examples help with durability and compliance review; blackhat and greyhat examples reveal pressure points, hooks, mechanisms, and funnel structures that may be driving spend but require careful adaptation before use.

The catalog is also built for global operators, with VSL and ad references spanning 14+ languages and different local idioms. That is a key advantage for Brazilian, LATAM, European, MENA, Indian, and non-native English affiliates who need to see how the same market desire is translated across cultures instead of only studying US English ads.

How to use the intelligence responsibly

The goal is modeling, not copying. Use Daily Intel to understand structure: hook, mechanism, proof, claim intensity, funnel depth, offer economics, and saturation stage. Then build original creative, review claims, and adapt the angle to the traffic source, country, language, and compliance requirements of the campaign.

A strong workflow compares multiple examples before acting. If the same mechanism appears across several languages, several advertisers, and several funnel variants, it may be a durable market signal. If the example appears only once or depends on an aggressive claim, treat it as a research clue rather than a campaign template.

• Model structure, not protected creative assets.
• Separate whitehat durability from blackhat persuasion pressure.
• Compare US English examples against LATAM, European, and other language variants.
• Use transcripts and funnel notes to build original briefs.
• Keep compliance review separate from market research.

Methodology and source context

Daily Intel pages are written from a research workflow that reviews active VSLs, Meta ad creatives, transcripts, UTMs, funnel paths, checkout steps, upsells, recovery sequences, and compliance-sensitive claim patterns. The goal is to explain observable market behavior, not to provide legal, medical, or platform policy advice.

For external context, readers should compare advertising and research decisions against authoritative primary references such as FTC health claims guidance, Meta advertising standards, and Meta Ad Library. Daily Intel adds the proprietary direct-response layer: blackhat, greyhat, and whitehat campaign pattern comparison across VSL-heavy niches and 14+ language markets.

For deeper evaluation, continue through Nutra niche intelligence directory, Parasite Cleanse Offers: Inside the 2026 Detox Ad Wave, Peptide Affiliate Offers: What's Actually Running in 2026, Blue Tonic Ads: Anatomy of a Weight Loss Ritual Hook, Coffee Loophole Ads: How the Hook Works & Who Runs It, and GLP-1 affiliate marketing intelligence. These related Daily Intel pages connect this topic to the relevant methodology, pricing, trust context, comparison path, or niche workflow.